Literature DB >> 15738379

Bortezomib-induced severe hepatitis in multiple myeloma: a case report.

Laura Rosiñol1, Silvia Montoto, Maria Teresa Cibeira, Joan Bladé.   

Abstract

Bortezomib is a novel proteasome inhibitor with significant antimyeloma activity. Its toxicity is manageable, and the most frequent adverse effects mainly consist of gastrointestinal symptoms, peripheral neuropathy, neuropatic pain, and thrombocytopenia. Severe liver toxicity has not been previously recognized. A patient with relapsed multiple myeloma who developed bortezomib-induced severe recurrent hepatitis is described. The importance of recognizing this rare potential toxicity is highlighted in order to discontinue this agent if liver adverse reaction is suspected.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15738379     DOI： 10.1001/archinte.165.4.464

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN： 0003-9926


  14 in total

1.  Cholestasis in a Patient of Multiple Myeloma: A Rare Occurrence of Bortezomib Induced Liver Injury.

Authors:  Ankur Jain; Pankaj Malhotra; Vikas Suri; Subhash Varma; Ashim Das; Suvradeep Mitra
Journal:  Indian J Hematol Blood Transfus       Date:  2016-03-01       Impact factor: 0.900

Review 2.  The future of proteasome inhibitors in relapsed/refractory multiple myeloma.

Authors:  Robert Z Orlowski
Journal:  Oncology (Williston Park)       Date:  2011-11-15       Impact factor: 2.990

3.  Detrimental effect of the proteasome inhibitor, bortezomib in bacterial superantigen- and lipopolysaccharide-induced systemic inflammation.

Authors:  Ashenafi Y Tilahun; Jayne E Theuer; Robin Patel; Chella S David; Govindarajan Rajagopalan
Journal:  Mol Ther       Date:  2010-04-06       Impact factor: 11.454

4.  The unfolded protein response transducer IRE1α prevents ER stress-induced hepatic steatosis.

Authors:  Kezhong Zhang; Shiyu Wang; Jyoti Malhotra; Justin R Hassler; Sung Hoon Back; Guohui Wang; Lin Chang; Wenbo Xu; Hongzhi Miao; Roberta Leonardi; Y Eugene Chen; Suzanne Jackowski; Randal J Kaufman
Journal:  EMBO J       Date:  2011-03-15       Impact factor: 11.598

Review 5.  The use of novel agents in multiple myeloma patients with hepatic impairment.

Authors:  Lindsay C Stansfield; Wilson I Gonsalves; Francis K Buadi
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

6.  Sustained remission and reversal of end-organ dysfunction in a patient with anaplastic myeloma.

Authors:  Mridul Agrawal; Jennifer Kanakry; Christina A Arnold; Daniel L Suzman; Luckson Mathieu; Yvette L Kasamon; Douglas E Gladstone; Richard F Ambinder; Nilanjan Ghosh
Journal:  Ann Hematol       Date:  2014-07       Impact factor: 3.673

7.  Hepatic failure caused by plasma cell infiltration in multiple myeloma.

Authors:  Fadi-E Rahhal; Robert-R Schade; Asha Nayak; Teresa A Coleman
Journal:  World J Gastroenterol       Date:  2009-04-28       Impact factor: 5.742

Review 8.  Proteasome inhibitors in the treatment of multiple myeloma.

Authors:  J J Shah; R Z Orlowski
Journal:  Leukemia       Date:  2009-09-10       Impact factor: 11.528

9.  UPR pathways combine to prevent hepatic steatosis caused by ER stress-mediated suppression of transcriptional master regulators.

Authors:  D Thomas Rutkowski; Jun Wu; Sung-Hoon Back; Michael U Callaghan; Sean P Ferris; Jahangir Iqbal; Robert Clark; Hongzhi Miao; Justin R Hassler; Jamie Fornek; Michael G Katze; M Mahmood Hussain; Benbo Song; Jayanth Swathirajan; Junying Wang; Grace D-Y Yau; Randal J Kaufman
Journal:  Dev Cell       Date:  2008-12       Impact factor: 12.270

10.  Proteasome dysfunction under compromised redox metabolism dictates liver injury in NASH through ASK1/PPARγ binodal complementary modules.

Authors:  Debajyoti Das; Avishek Paul; Abhishake Lahiri; Moumita Adak; Sujay K Maity; Ankita Sarkar; Sandip Paul; Partha Chakrabarti
Journal:  Redox Biol       Date:  2021-06-11       Impact factor: 11.799
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.